{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:00:38Z","timestamp":1791471638413,"version":"4.3.4"},"reference-count":49,"publisher":"American Society for Microbiology","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100007155","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X020258\/1"],"award-info":[{"award-number":["MR\/X020258\/1"]}],"id":[{"id":"10.13039\/501100007155","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Global Health R&D of Merck Healthcare, Ares Trading S.A."},{"name":"Community Jameel"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Preventive treatment (chemoprevention) is a key intervention for reducing the burden of\n                      <jats:italic toggle=\"yes\">Plasmodium falciparum<\/jats:italic>\n                      malaria in children. The impact of the current widely used drug combination, sulfadoxine-pyrimethamine-amodiaquine (SP-AQ), is challenged by emerging drug resistance and adherence to multi-day dosing. Cabamiquine is a novel antimalarial with activity against liver- and blood-stage malaria parasites, administered as a single dose, and under development in combination with pyronaridine. We used mathematical modeling to translate early phase 1 clinical results into estimates of its potential impact as malaria chemoprevention. Pharmacokinetic-pharmacodynamic (PKPD) models of cabamiquine and pyronaridine were combined, assuming Bliss independence, to estimate time-varying protection against infection. PKPD results were incorporated into an established individual-based malaria transmission model to estimate the impact of seasonal malaria chemoprevention (SMC) across settings with differing transmission and seasonality. Cabamiquine-pyronaridine was predicted to provide protection of &gt;95% for approximately 4 weeks, slightly outperforming SP-AQ even in children who fully adhere to SP-AQ treatment. Six weeks after treatment, cabamiquine-pyronaridine protection dropped for the regimens containing &lt;200 mg cabamiquine, but the combination could still outperform SP-AQ at doses \u2265200 mg. If deployed as SMC, a longer duration of protection may enable fewer, more widely spaced treatment cycles while maintaining impact, improving projected cost-effectiveness. Cabamiquine-pyronaridine shows strong potential as a next-generation single-dose chemoprevention regimen, supporting continued clinical development and evaluation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00434-26","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:42:52Z","timestamp":1791470572000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Modeling the potential effect of cabamiquine-pyronaridine for chemoprevention against\n                    <i>Plasmodium falciparum<\/i>\n                    malaria"],"prefix":"10.1128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7202-6873","authenticated-orcid":true,"given":"Lucy C.","family":"Okell","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/041kmwe10","id-type":"ROR","asserted-by":"publisher"}],"name":"MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9114-7793","authenticated-orcid":true,"given":"Perrine","family":"Courlet","sequence":"additional","affiliation":[{"name":"Merck Institute for Pharmacometrics, Ares Trading S.A. (an affiliate of Merck KGaA, Darmstadt, Germany)","place":["Lausanne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Venezia","sequence":"additional","affiliation":[{"name":"The Healthcare Business of Merck KGaA","place":["Darmstadt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Oeuvray","sequence":"additional","affiliation":[{"name":"Global Health R&D of Merck Healthcare, Ares Trading S.A. (an affiliate of Merck KGaA, Darmstadt, Germany)","place":["Eysins, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9610-2962","authenticated-orcid":true,"given":"Claudia","family":"Demarta","sequence":"additional","affiliation":[{"name":"Global Health R&D of Merck Healthcare, Ares Trading S.A. (an affiliate of Merck KGaA, Darmstadt, Germany)","place":["Eysins, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5654-8919","authenticated-orcid":true,"given":"Thomas","family":"Spangenberg","sequence":"additional","affiliation":[{"name":"Global Health R&D of Merck Healthcare, Ares Trading S.A. (an affiliate of Merck KGaA, Darmstadt, Germany)","place":["Eysins, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Okebe","sequence":"additional","affiliation":[{"name":"Global Health R&D of Merck Healthcare, Ares Trading S.A. (an affiliate of Merck KGaA, Darmstadt, Germany)","place":["Eysins, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"WHO. 2022. WHO guidelines for malaria. World Health Organization. Geneva"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32227-3"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.23-0481"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06708-9"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001578"},{"key":"e_1_3_3_7_2","unstructured":"Malaria consortium. 2022. Available from: https:\/\/www.malariaconsortium.org\/blog\/smc-new-geographies\/"},{"key":"e_1_3_3_8_2","unstructured":"WHO. 2021. World malaria report 2021. World Health Organization Geneva. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240040496"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1707"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-022-04171-0"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4381"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02181-19"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(26)00233-1"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00891-23"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107196"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12875"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.1c00640"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2020.1807940"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000324"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4136"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00423-5"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00416-8"},{"key":"e_1_3_3_23_2","unstructured":"Charles G Winskill P Topazian H Challenger J Fitzjohn R Sheppard R Brewer T McCain K Haile L. 2024. Malariasimulation: an individual based model for malaria. R package version 1.6.0"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.2014.2657"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-9-136"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004376"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04923-14"},{"key":"e_1_3_3_28_2","unstructured":"Cuomo-Dannenburg G. 2024. Modelling the potential suitability of seasonal malaria chemoprevention in settings of high-grade sulfadoxine-pyrimethamine resistance PhD thesis"},{"key":"e_1_3_3_29_2","unstructured":"Thompson H. 2022. Modelling the public health impact of second-generation malaria vaccines PhD thesis Imperial College London"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.12688\/gatesopenres.14287.2"},{"key":"e_1_3_3_31_2","unstructured":"Zongo I Haro A Roh ME Zerbo RO Huang L Sawadogo A Legac J Som\u00e9 AF Yerbanga RS Wallender E Aweeka F Ou\u00e9draogo JB Rosenthal PJ. 2023. Associations between sulfadoxine-pyrimethamine + amodiquine concentrations malaria incidence and resistance markers in children receiving seasonal malaria chemoprevention in Burkina Faso. ASTMH Abstract Book 2023. https:\/\/d1lx8xdon3af7k.cloudfront.net\/ASTMH_2023_Annual_Meeting_Abstract_Book_All_Abstracts_621c16a89d.pdf."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00816-2"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00239-X"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-3305-4-153"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1879"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30475-7"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.03.021"},{"key":"e_1_3_3_38_2","unstructured":"International monetary fund. 2026. World economic outlook databases. https:\/\/www.imf.org\/en\/publications\/sprolls\/world-economic-outlook-databases."},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00725-4"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002175"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30325-9"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235631"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14451"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58326-z"},{"key":"e_1_3_3_45_2","volume-title":"ASTMH Annual Meeting 2025\u2014Abstract 7796","author":"Yaro JBB","year":"2025","unstructured":"Yaro JBB, Serme SS, Barry A, Ouedraogo A, Leirana Moreno M, Gmeiner M, Byrne I, LeiranaRJ, Emilie S, SoulamII, Grignard LL, Soremekun SS, Koele SL, Ter HRL, Ouedraogo AZ, Sawadogo WJ, Hien D, Bradley J, Sirima SB, Bousema T, Drakeley C, Tiono AB. 2025. Understanding and maximizing the community impact of seasonal malaria chemoprevention: a randomized controlled trial in a high malaria burden setting. ASTMH Annual Meeting 2025\u2014Abstract 7796."},{"key":"e_1_3_3_46_2","unstructured":"UN News. 2025. Malaria vaccine price cut set to protect 7 million more children by 2030. Available from: https:\/\/news.un.org\/en\/story\/2025\/11\/1166432. Retrieved 26 Feb 2026."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40974-8"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00252-8"},{"key":"e_1_3_3_49_2","unstructured":"World health organisation. 2026. World health organisation. compendium of molecular markers for antimalarial drug resistance Available from: https:\/\/www.who.int\/tools\/compendium-of-molecular-markers-for-antimalarial-drug-resistance\/results. Retrieved 15 Jul 2026."},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30220-6"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00434-26","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00434-26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:42:55Z","timestamp":1791470575000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00434-26"}},"subtitle":[],"editor":[{"given":"Audrey","family":"Odom John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":49,"alternative-id":["10.1128\/aac.00434-26"],"URL":"https:\/\/doi.org\/10.1128\/aac.00434-26","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"2026-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00434-26"}}